PLpro inhibitor

CAS No. 1093070-14-4

PLpro inhibitor ( —— )

Catalog No. M22162 CAS No. 1093070-14-4

PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor(IC50 of 2.6 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 174 In Stock
5MG 260 In Stock
10MG 372 In Stock
25MG 619 In Stock
50MG 881 In Stock
100MG 1188 In Stock
500MG 2367 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PLpro inhibitor
  • Note
    Research use only, not for human use.
  • Brief Description
    PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor(IC50 of 2.6 uM).
  • Description
    PLpro inhibitor is a potent papain-like protease (PLpro) inhibitor(IC50 of 2.6 uM)
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    papain-like protease (PLpro)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1093070-14-4
  • Formula Weight
    346.42
  • Molecular Formula
    C22H22N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 40 mg/mL (115.47 mM)
  • SMILES
    C[C@@H](NC(=O)c1cc(NC(C)=O)ccc1C)c1cccc2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24.
molnova catalog
related products
  • VK-II-36

    VK-II-36, a carvedilol analog, suppresses sarcoplasmic reticulum (SR) Ca(2+) release but does not block the β-receptor.

  • Linzagolix

    Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.

  • 22'-Cyclouridine

    22'-Cyclouridine is a research tool for antiviral and anticancer studies.